Senseonics (NYSE: SENS) is one of 25 public companies in the “Process control instruments” industry, but how does it contrast to its peers? We will compare Senseonics to similar businesses based on the strength of its earnings, dividends, analyst recommendations, valuation, risk, institutional ownership and profitability.
This table compares Senseonics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Senseonics has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Senseonics’ peers have a beta of 0.52, meaning that their average share price is 48% less volatile than the S&P 500.
Earnings & Valuation
This table compares Senseonics and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Senseonics||$21.30 million||-$115.55 million||-0.55|
|Senseonics Competitors||$2.29 billion||$361.44 million||25.82|
Senseonics’ peers have higher revenue and earnings than Senseonics. Senseonics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
24.4% of Senseonics shares are owned by institutional investors. Comparatively, 62.5% of shares of all “Process control instruments” companies are owned by institutional investors. 7.4% of Senseonics shares are owned by insiders. Comparatively, 10.1% of shares of all “Process control instruments” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a summary of current ratings and price targets for Senseonics and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Process control instruments” companies have a potential upside of 1.03%. Given Senseonics’ peers higher probable upside, analysts plainly believe Senseonics has less favorable growth aspects than its peers.
Senseonics peers beat Senseonics on 8 of the 10 factors compared.
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes for a period of up to 90 and 180 days. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.